Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879195 | 0.86 | ALDH1A1 (0.50) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL24150465 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL250035 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL29083401 | 0.78 | ALDH1A1 (0.56) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL29568160 | 0.77 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL91981 | 0.77 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL55593 | 0.77 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL29569367 | 0.77 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL1562746 | 0.75 | ALDH1A1 (0.56) | ALDH1A1CYP3A4MAPTTHRBKDM4E | |
| Ammonia Solution, Strong SCHEMBL1854404 | 0.75 | ALDH1A1 (0.57) | ALDH1A1CYP3A4MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8552043-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-7435752-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435752-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435752-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1789039-A2 | S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Ardea Biosciences, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006026356-A2 | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | ALDH1A1 1407/4885CYP3A4 254/4885MEN1 4821/4885 |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | NQO2, NAT1, QPCT | ALDH1A1 903/4885CYP3A4 529/4885MEN1 4854/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | ALDH1A1 1407/4885CYP3A4 254/4885MEN1 4821/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | ALDH1A1 1574/4885CYP3A4 171/4885MEN1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.